Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity

• Main Authors: Ashraf K. El-Damasy (Author), Heewon Jin (Author), Jung Woo Park (Author), Hyun Ji Kim (Author), Hanan Khojah (Author), Seon Hee Seo (Author), Ju-Hyeon Lee (Author), Eun-Kyoung Bang (Author), Gyochang Keum (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The design of kinase inhibitors targeting the oncogenic kinase BCR-ABL constitutes a promising paradigm for treating chronic myeloid leukaemia (CML). Nevertheless, the efficacy of imatinib, the first FDA-approved targeted therapy for CML, is curbed by the emergence of resistance. Herein, we report t...